Bovie inks J-Plasma distribution deal with Arteriocyte

Bovie Medical (NYSE:BVX) said this week it inked a sales channel partnership agreement with Arteriocyte Medical Systems to sell Bovie’s J-Plasma to its network of plastic surgeons.

Through the deal, Arteriocyte will offer J-Plasma through its U.S. sales network, which Clearwater, Fla.-based Bovie said will significantly expand its use in office-based practices.

“We are delighted to sign this agreement with Arteriocyte, a company with an exemplary reputation in selling innovative cellular therapy based medical devices. J-Plasma’s precision and lack of thermal spread make it a natural fit for the plastic surgeon, and Arteriocyte’s nationwide reach and complementary product portfolio will significantly raise awareness of the technology, and complement our existing sales efforts. This partnership is an important milestone in our strategy to scale J-Plasma across multiple specialties, leveraging the different applications for this unique surgical technology,” Bovie CEO Robert Gershon said in a press release.

Bovie Medical said Arteriocyte’s sales team has previous experience in biologics and medical devices used in plastic surgery, as well as a portfolio of complementary products.

“J-Plasma’s potential to substantially reduce patient down-time aligns well with our strategic priorities, and we look forward to successfully launching this new product to our network of plastic surgeons nationwide,” Arteriocyte CEO Donald Brown said in prepared remarks.

In April, Bovie Medical said it launched its J-Plasma compatible Precise 360 hand piece designed for prostate surgery procedures.

The newly released J-Plasma Precise 360 handpiece is designed with an angled and rotating tip to allow operating surgeons to access to structures that would be difficult to reach with straight laparoscopic devices, the company said.